AbbVie's Upadacitinib Extended-Release Tablets Considered for Priority Review for New Indication

Stock News03-13 12:25

On March 12, the CDE website indicated that a new indication for AbbVie's Upadacitinib extended-release tablets is being considered for priority review. The proposed use is for the treatment of non-segmental vitiligo in adults and adolescents aged 12 and above. Upadacitinib is a selective JAK inhibitor and a key product for AbbVie, with global sales reaching $8.304 billion in 2025, a 39.07% increase.

The priority review application pertains to a new indication: non-segmental vitiligo in adults and adolescents aged 12 and above. Regarding this indication, in February of this year, AbbVie announced that it had submitted a new application to the U.S. FDA and the European EMA for the use of Upadacitinib in treating non-segmental vitiligo (NSV) in adults and adolescents.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment